Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05308446
Title Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Cetuximab + Encorafenib

Cetuximab + Encorafenib + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST